Clin2
NCT05430971Likely a fitRecruiting

BPDCN international registry for patients to be followed over time

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Part of Blood & lymphatic, Cancer, Skin clinical trials.

This trial is a patient registry for people with blastic plasmacytoid dendritic cell neoplasm (BPDCN). It helps researchers learn more about the disease by collecting information from patients as they get care.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
200 people
Ages
Any age
Study type
Observational

Who can take part

  • You must have a confirmed diagnosis of BPDCN.
  • You (or your legal guardian) must be able to sign a consent form to join.
  • You will need to follow the registry’s instructions for sharing medical information.
  • There are no listed medical reasons to exclude you in the criteria provided.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07785180Recruiting
Observational study of BPDCN patients treated with chemotherapy

This study looks back at the health records of people who were treated for BPDCN (a rare blood cancer) with chemotherapy as their first treatment. The goal is to learn more about how the disease progresses and how well treatments work in the real world. If you meet the criteria, your past medical data may be included.

Aarhus
NCT07785154Recruiting
Tracking health for people with blastic plasmacytoid dendritic cell neoplasm

This study follows people with a rare blood cancer called BPDCN who are starting or recently started a medicine called Elzonris (tagraxofusp). It collects health information to see how the treatment works over time.

Innsbruck
NCT07007052Recruiting· Phase 2
Tagraxofusp plus venetoclax for newly diagnosed BPDCN

This trial tests a combination of two targeted drugs (tagraxofusp and venetoclax) for people with a rare blood cancer called BPDCN who have not been treated before. The goal is to see if this combination is safe and effective as a first treatment.

Amiens
NCT06552078Recruiting
Biobank Registry for Bile Duct and Pancreas Diseases

This trial is building a registry (a collection of samples and health information) for people with bile duct or pancreas diseases. By joining, you help researchers study these conditions to improve future treatments.

Milan
NCT03125707Recruiting
Registry for adults with certain BCR-ABL1–negative blood cancers

This study keeps a patient registry to collect information about people with specific myeloid blood neoplasms (a type of blood cancer). It helps researchers understand these conditions over time and may improve how patients are cared for in the future.

Augsburg
NCT02869581Recruiting
Pancreatic tumor patient registry

This study builds a database of people diagnosed with pancreatic tumors. It may help researchers better understand these cancers by collecting medical information over time.

Marseille, Bouches du Rhone

Hear when a new Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.